

Hideyuki Hyogo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6430918/publications.pdf>

Version: 2024-02-01

80
papers

4,013
citations

159358

30
h-index

118652

62
g-index

82
all docs

82
docs citations

82
times ranked

5107
citing authors

#	ARTICLE	IF	CITATIONS
1	Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. <i>Gastroenterology</i> , 2016, 150, 626-637.e7.	0.6	628
2	Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. <i>Journal of Gastroenterology</i> , 2012, 47, 586-595.	2.3	421
3	Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. <i>BMC Gastroenterology</i> , 2012, 12, 2.	0.8	295
4	A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2011, 46, 257-268.	2.3	185
5	Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. <i>Metabolism: Clinical and Experimental</i> , 2008, 57, 1711-1718.	1.5	184
6	Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1112-1119.	1.4	164
7	Advanced Glycation End Products (AGEs) and their Involvement in Liver Disease. <i>Current Pharmaceutical Design</i> , 2008, 14, 969-972.	0.9	123
8	Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. <i>Journal of Gastroenterology</i> , 2014, 49, 1477-1484.	2.3	119
9	Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2011, 46, 1300-1306.	2.3	108
10	Palmitate-induced lipotoxicity is crucial for the pathogenesis of nonalcoholic fatty liver disease in cooperation with gut-derived endotoxin. <i>Scientific Reports</i> , 2018, 8, 11365.	1.6	85
11	Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016, 6, 35282.	1.6	77
12	Involvement of <i>Porphyromonas gingivalis</i> in the progression of non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2018, 53, 269-280.	2.3	73
13	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040. <i>Hepatology International</i> , 2021, 15, 366-379.	1.9	71
14	The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. <i>Journal of Gastroenterology</i> , 2018, 53, 1216-1224.	2.3	68
15	<sc>HOMA</sc>: An independent predictor of advanced liver fibrosis in nondiabetic nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1390-1395.	1.4	67
16	A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycomarkers. <i>Hepatology</i> , 2015, 62, 1433-1443.	3.6	61
17	Characteristics of obese nonalcoholic fatty liver disease: Effect of genetic and environmental factors. <i>Hepatology Research</i> , 2016, 46, 1011-1018.	1.8	60
18	lpravgliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD. <i>Hepatology Communications</i> , 2022, 6, 120-132.	2.0	60

#	ARTICLE	IF	CITATIONS
19	Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- α -lowering property. <i>Digestive and Liver Disease</i> , 2012, 44, 492-496.	0.4	50
20	Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. <i>Journal of Gastroenterology</i> , 2016, 51, 586-596.	2.3	49
21	Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2016, 6, 28814.	1.6	47
22	Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. <i>Hepatology Research</i> , 2015, 45, 656-662.	1.8	42
23	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1907.	1.8	42
24	The impact of PNPLA3 and JAZF1 on hepatocellular carcinoma in non-viral hepatitis patients with type 2 diabetes mellitus. <i>Journal of Gastroenterology</i> , 2016, 51, 370-379.	2.3	41
25	Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. <i>Journal of Digestive Diseases</i> , 2015, 16, 505-512.	0.7	40
26	Role of conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, 607-617.	1.8	40
27	Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 507-517.	0.9	38
28	Prevalence of pruritus in patients with chronic liver disease: A multicenter study. <i>Hepatology Research</i> , 2018, 48, E252-E262.	1.8	37
29	LDL-Migration Index (LDL-MI), an Indicator of Small Dense Low-Density Lipoprotein (sdLDL), Is Higher in Non-Alcoholic Steatohepatitis than in Non-Alcoholic Fatty Liver: A Multicenter Cross-Sectional Study. <i>PLoS ONE</i> , 2014, 9, e115403.	1.1	36
30	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. <i>Oncology</i> , 2018, 94, 215-222.	0.9	33
31	A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD. <i>Scientific Reports</i> , 2018, 8, 10434.	1.6	32
32	The Association between Glyceraldehyde-Derived Advanced Glycation End-Products and Colorectal Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1855-1863.	1.1	30
33	Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 370-379.	2.4	30
34	Epidemiological survey of hemoglobin A1c and liver fibrosis in a general population with nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 296-303.	1.8	29
35	Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non or Non Hepatocellular Carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2015, 29, 480-484.	0.9	28
36	Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1780-1786.	1.4	28

#	ARTICLE	IF	CITATIONS
37	Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2020, 98, 787-797.	0.9	26
38	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2275-2284.	1.4	26
39	Biphasic effect of alcohol intake on the development of fatty liver disease. <i>Journal of Gastroenterology</i> , 2015, 50, 1114-1123.	2.3	24
40	Significance of non-alcoholic fatty liver disease in Crohn's disease: A retrospective cohort study. <i>Hepatology Research</i> , 2017, 47, 872-881.	1.8	22
41	FIB-4 First in the Diagnostic Algorithm of Metabolic-Dysfunction-Associated Fatty Liver Disease in the Era of the Global Metabodemic. <i>Life</i> , 2021, 11, 143.	1.1	22
42	Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring. <i>PLoS ONE</i> , 2018, 13, e0195028.	1.1	21
43	ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. <i>Hepatology Communications</i> , 2020, 4, 1624-1636.	2.0	21
44	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. <i>Anticancer Research</i> , 2016, 36, 3523-9.	0.5	21
45	Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma. <i>European Radiology</i> , 2015, 25, 3272-3281.	2.3	19
46	Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. <i>Hepatology Research</i> , 2016, 46, E146-53.	1.8	19
47	<i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2018, 48, 521-528.	1.8	19
48	Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1626-1632.	1.4	19
49	Upper limit of normal serum alanine aminotransferase levels in Japanese subjects. <i>Hepatology Research</i> , 2014, 44, 1196-1207.	1.8	18
50	Targeted next-generation sequencing and fine linkage disequilibrium mapping reveals association of PNPLA3 and PARVB with the severity of nonalcoholic fatty liver disease. <i>Journal of Human Genetics</i> , 2014, 59, 241-246.	1.1	18
51	Prediction of Nonalcoholic Fatty Liver Disease Using Noninvasive and Non-Imaging Procedures in Japanese Health Checkup Examinees. <i>Diagnostics</i> , 2021, 11, 132.	1.3	18
52	Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. <i>PLoS ONE</i> , 2020, 15, e0219412.	1.1	17
53	Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. <i>BMC Gastroenterology</i> , 2021, 21, 306.	0.8	17
54	Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation. <i>Hepatology Research</i> , 2015, 45, 1047-1054.	1.8	16

#	ARTICLE	IF	CITATIONS
55	Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases. <i>European Journal of Radiology</i> , 2015, 84, 1540-1545.	1.2	16
56	Choline Deficiency Causes Colonic Type II Natural Killer T (NKT) Cell Loss and Alleviates Murine Colitis under Type I NKT Cell Deficiency. <i>PLoS ONE</i> , 2017, 12, e0169681.	1.1	14
57	Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with nonalcoholic fatty liver disease: A multicenter study. <i>Hepatology Research</i> , 2020, 50, 955-965.	1.8	12
58	Efficacy of probucol for the treatment of nonalcoholic steatohepatitis with dyslipidemia: An open-label pilot study. <i>Hepatology Research</i> , 2014, 44, 429-435.	1.8	11
59	Predictive value of cytokeratin-18 fragment levels for diagnosing steatohepatitis in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 1451-1458.	0.8	10
60	Uric acid levels decrease with fibrosis progression in patients with nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2014, 47, 1138-1139.	0.8	9
61	Morbidly obese patient with nonalcoholic steatohepatitis-related cirrhosis who died from sepsis caused by dental infection of <i>Porphyromonas gingivalis</i> : A case report. <i>Hepatology Research</i> , 2016, 46, E210-5.	1.8	9
62	Osteodystrophy in Cholestatic Liver Diseases Is Attenuated by Anti- β -Glutamyl Transpeptidase Antibody. <i>PLoS ONE</i> , 2015, 10, e0139620.	1.1	8
63	Evaluation of postprandial hypoglycemia in patients with nonalcoholic fatty liver disease by oral glucose tolerance testing and continuous glucose monitoring. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 797-805.	0.8	8
64	Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 320.	1.7	8
65	Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report. <i>Hepatology Research</i> , 2015, 45, 705-710.	1.8	5
66	Serum levels of pigment epithelium-derived factor (PEDF) are independently associated with procollagen III N-terminal peptide levels in patients with nonalcoholic fatty liver disease. <i>Clinical Biochemistry</i> , 2012, 45, 1554-1557.	0.8	4
67	Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance. <i>Digestive and Liver Disease</i> , 2012, 44, 935-939.	0.4	4
68	The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2017, 52, 253-262.	2.3	4
69	Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients. <i>Clinical and Experimental Medicine</i> , 2014, 14, 45-51.	1.9	2
70	Infection phase is a predictor of pruritus in patients with hepatitis B virus infection. <i>Biomedical Reports</i> , 2019, 11, 63-69.	0.9	1
71	Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 491-498.	0.9	1
72	Reply to the letter by I. Tasci regarding "Clinical usefulness of AGEs as a biomarker for the attenuation of NASH". <i>Journal of Gastroenterology</i> , 2010, 45, 781-781.	2.3	0

#	ARTICLE	IF	CITATIONS
73	Reply to the letter by Y. Yilmaz regarding "the AGEs"RAGE axis and nonalcoholic steatohepatitis". Journal of Gastroenterology, 2010, 45, 784-784.	2.3	0
74	sRAGE is associated with low waist circumference and Hb levels in NAFLD. Open Medicine (Poland), 2013, 8, 830-834.	0.6	0
75	A case of dual oral therapy for elderly patients with acute hepatitis C. Acta Hepatologica Japonica, 2017, 58, 197-201.	0.0	0
76	Self-expandable Metallic Stent for Obstructive Colorectal Cancer in Our Hospital: Evaluation of Short-term Benefit. Journal of the Japanese Association of Rural Medicine, 2021, 69, 506-509.	0.0	0
77	Title is missing!. , 2020, 15, e0219412.		0
78	Title is missing!. , 2020, 15, e0219412.		0
79	Title is missing!. , 2020, 15, e0219412.		0
80	Title is missing!. , 2020, 15, e0219412.		0